Host-Salmonella interaction: Human trials

Microbes and Infection

Volumn 3, Issue 14-15, 2001, Pages 1271-1279

  Levine, Myron M ^a   Tacket, Carol O ^a   Sztein, Marcelo B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Immunity, cellular; Immunity, humoral; Salmonella typhi; T lymphocytes, cytotoxic; Typhoid vaccines

Indexed keywords

TYPHOID VACCINE;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL MUTATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA ENTERICA; SALMONELLA TYPHI; SALMONELLOSIS; STRAIN DIFFERENCE; T LYMPHOCYTE; TYPHOID FEVER; VACCINATION;

SALMONELLA; SALMONELLA ENTERICA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI; SALMONELLA TYPHI;

EID: 0035671804     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01487-3     Document Type: Review

References (49)

1. Typhoid fever; pathogenesis and immunologic control
2. Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection
3. Immunity of cholera in man: Relative role of antibacterial versus antitoxic immunity
4. Immunity to enterotoxigenic Escherichia coli
5. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: Clinical experience and implications for Shigella infectivity
6. Attenuated streptomycin-dependent Salmonella typhi oral vaccine: Potential deleterious effects of lyophilization
7. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a live oral vaccine
8. Typhoid fever vaccines
9. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi
10. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans
11. Protective activity of Vi polysaccharide vaccine against typhoid fever
12. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report
13. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines
14. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals
15. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam
16. Isolation and characterization of gal E mutant Ty21a of Salmonella typhi: A candidate strain for a live oral typhoid vaccine
17. Typhoid vaccines come of age
18. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans
19. Comparison of the safety and immunogenicity of aroC,aroD and cya,crp Salmonella typhi strains in adult volunteers
20. Construction of genetically-defined double aro mutants of Salmonella typhi
21. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain
22. Evaluation in volunteers of a candidate live oral attenuated S. typhi vector vaccine
23. Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model
24. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors
25. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
26. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers
27. Characterization of defensin resistance phenotypes associated with mutations in the phoP-virulence regulon of Salmonella typhimurium
28. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence
29. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers
30. Recombinant Salmonella vectors in vaccine development
31. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the ASD balanced lethal system
32. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909
33. Progress in vaccines against typhoid fever
34. Vi serology in detection of chronic Salmonella typhi carriers in an endemic area
35. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers
36. Characterization of defined ompR mutants of Salmonella typhi: ompR is involved in the regulation of Vi polysaccharide expression
37. The RcsB-RcsC regulatory system of Salmonella typhi differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity
38. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine
39. Identification of an intestinal immune response using peripheral blood lymphocytes
40. Chilean Typhoid Committee, Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation
41. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial
42. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: A field trial in an endemic area
43. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine
44. Specific immune response in humans following rectal delivery of live typhoid vaccine
45. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: Strain construction and safety and immunogenicity in humans
46. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C
47. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization
48. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: Three year results
49. Duration of efficacy of ty21a, attenuated Salmonella typhi live oral vaccine